Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

[Serotonergic system as a therapeutic target in multiple sclerosis].

Sviridova AA, Melnikov MV, Belousova OO, Rogovskii VS, Pashenkov MV, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):64-72. doi: 10.17116/jnevro20191192264. Russian.

PMID:
31156244
2.

Synergistic interactions between NOD receptors and TLRs: Mechanisms and clinical implications.

Pashenkov MV, Murugina NE, Budikhina AS, Pinegin BV.

J Leukoc Biol. 2019 Apr;105(4):669-680. doi: 10.1002/JLB.2RU0718-290R. Epub 2018 Dec 5. Review.

PMID:
30517768
3.

A cell-based test system for the assessment of pharmacokinetics of NOD1 and NOD2 receptor agonists.

Dagil YA, Sharova VS, Pinegin BV, Pashenkov MV.

Int Immunopharmacol. 2018 Oct;63:94-100. doi: 10.1016/j.intimp.2018.07.037. Epub 2018 Aug 1.

PMID:
30077058
4.

NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases.

Pashenkov MV, Dagil YA, Pinegin BV.

Int Immunopharmacol. 2018 Jan;54:385-400. doi: 10.1016/j.intimp.2017.11.036. Epub 2017 Dec 5. Review.

PMID:
29207344
5.

The Role of the p38-MNK-eIF4E Signaling Axis in TNF Production Downstream of the NOD1 Receptor.

Pashenkov MV, Balyasova LS, Dagil YA, Pinegin BV.

J Immunol. 2017 Feb 15;198(4):1638-1648. doi: 10.4049/jimmunol.1600467. Epub 2017 Jan 13.

6.

The Dual NOD1/NOD2 Agonism of Muropeptides Containing a Meso-Diaminopimelic Acid Residue.

Dagil YA, Arbatsky NP, Alkhazova BI, L'vov VL, Mazurov DV, Pashenkov MV.

PLoS One. 2016 Aug 11;11(8):e0160784. doi: 10.1371/journal.pone.0160784. eCollection 2016.

7.

Complexes of DNA with the Antimicrobial Peptide LL37 Augment NK Cell Functions by Inducing Type I Interferon Production from Circulating Monocytes and Plasmacytoid Predendritic Cells.

Pinegin BV, Pashenkov MV, Kulakov VV, Murugin VV, Zhmak MN.

J Interferon Cytokine Res. 2015 Nov;35(11):850-8. doi: 10.1089/jir.2014.0203. Epub 2015 Aug 10.

PMID:
26258404
8.

Reduced degranulation of NK cells in patients with frequently recurring herpes.

Murugin VV, Zuikova IN, Murugina NE, Shulzhenko AE, Pinegin BV, Pashenkov MV.

Clin Vaccine Immunol. 2011 Sep;18(9):1410-5. doi: 10.1128/CVI.05084-11. Epub 2011 Jul 6.

9.

Muropeptides trigger distinct activation profiles in macrophages and dendritic cells.

Pashenkov MV, Popilyuk SF, Alkhazova BI, L'vov VL, Murugin VV, Fedenko ES, Khaitov RM, Pinegin BV.

Int Immunopharmacol. 2010 Aug;10(8):875-82. doi: 10.1016/j.intimp.2010.04.025. Epub 2010 May 10.

PMID:
20438865

Supplemental Content

Loading ...
Support Center